Table 3.
Pathways enriched in genes generating circRNAs expressed predominantly in human pancreatic islets
| A. | |||
| Pathways enriched in genes hosting circRNAs not seen in other tissues | |||
| Pathway | p-value | Number of Genes | Genes |
| Pancreatic secretion | < 0.0001 | 5 | CELA3A, CFTR, CPA1, KCNQ1, PNLIPRP2 |
| B. | |||
| Pathways enriched in genes generating the top 10% the most abundantly-expressed circRNAs in islets | |||
| Pathway | p-value | Number of Genes | Genes |
| Hematopoietic Stem Cell Gene Regulation | < 0.0001 | 4 | CREBBP, EP300, FOXO3, GABPB1 |
| Pathways affected in Adenoid Cystic Carcinoma | 0.010 | 6 | CREBBP,EP300, FOXO3, KANSL1, KMT2C, MAML3 |
| Attenuation phase | 0.020 | 3 | CREBBP, DNAJB1, EP300 |
| RUNX3 regulates NOTCH signaling | 0.020 | 3 | CREBBP, EP300, MAML3 |
| Lysine degradation | 0.030 | 5 | ASHIL, EHMT1, KMT2C, PLOD1, SETD3 |
GO pathways analysis to identify pathways enriched in the host genes of A. novel RNAs not previously characterised in other tissues or B. the top 10% most abundant circRNAs in human islets are presented here. Number of genes = number of differentially-expressed genes in each pathway